Clearside Biomedical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLSD research report →
About the company
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema.
- CEO
- George Lasezkay
- IPO
- 2016
- Employees
- 32
- HQ
- Alpharetta, GA, US
Price Chart
- Market Cap
- $2.15M
- P/E
- -0.03
- P/S
- 0.22
- P/B
- -0.01
- EV/EBITDA
- -5.71
- Div Yield
- 0.00%
- Gross Margin
- 89.02%
- Op Margin
- -523.09%
- Net Margin
- -618.26%
- ROE
- 37.73%
- ROIC
- -170.86%
- Revenue
- $1.66M · -79.77%
- Net Income
- $-34,352,000 · -5.75%
- EPS
- $-7.05 · 11.32%
- Op Income
- $-28,882,000
- FCF YoY
- -28.94%
- 52W High
- $17.10
- 52W Low
- $0.31
- 50D MA
- $2.87
- 200D MA
- $8.22
- Beta
- 1.79
- Avg Volume
- 264.40K
Get TickerSpark's AI analysis on CLSD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 20 | WHITMORE BRADFORD T | buy | 50,000 |
| Aug 12, 20 | WHITMORE BRADFORD T | buy | 300,000 |
Our CLSD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CLSD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.